Genmab — Maj 2021
-
innovaTV 208 for Ovarian cancer stops recruiting at 98 patients (222 anticipated) https://clinicaltrials.gov/ct2/history/NCT03657043?A=30&B=31&C=merged#StudyPageTop
-
E L is that to be seen as negative?
-
the way i see it, they either got results that are sooo good that the go straight to a Ph3, or the results disappointed and they stop the efforts on Ovarian cancer( which seems more likely doesn't it...) or maybe they simply think that those 98 can give them all the info they need to make the next step (doubt that..)
-
Both CHRYSALIS/Amivantamab and the GEN1042 trials had their Estimated Primary Completion Date extended https://clinicaltrials.gov/ct2/history/NCT02609776?A=54&B=55&C=merged#StudyPageTop .https://clinicaltrials.gov/ct2/history/NCT04083599?A=3&B=4&C=merged#StudyPageTop which is a similar situation where i wonder if that is a good or a bad thing
-
-
Man kunne skrive til, [email protected]. Måske de svarer lige så hurtigt som Andrew.
-
Når et studie standses så tidligt før tid så er det hvis mere reglen end undtagelsen det er dårligt nyt. Så vi skal ud i undtagelsen her hvis det er.... Der bør relativt hurtigt komme meddelelse med begrundelse
-
Er studiet ikke forsat aktivt og rekruttering stoppet?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind